

TFW

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

**In re application of:** Combadiere et al.**Application No.** 10/700,313**Filed:** October 31, 2003**Confirmation No.** 5461**For:** CC CHEMOKINE RECEPTOR 5 DNA,  
NEW ANIMAL MODELS AND  
THERAPEUTIC AGENTS FOR HIV  
INFECTION**Examiner:****Art Unit:** 1616**Attorney Reference No.** 4239-66645-01**CERTIFICATE OF MAILING**

I hereby certify that this paper and the documents referred to as being attached or enclosed herewith are being deposited with the United States Postal Service as First Class Mail in an envelope addressed to: COMMISSIONER FOR PATENTS, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450 on the date shown below.

Attorney  
for Applicant(s)

Tanya M. Harding, Ph.D.

Date Mailed April 8, 2005**INFORMATION DISCLOSURE STATEMENT  
PURSUANT TO 37 C.F.R. § 1.97(b)(3)**

COMMISSIONER FOR PATENTS  
P.O. BOX 1450  
ALEXANDRIA, VA 22313-1450

Listed on the accompanying form PTO-1449 are two English-language documents. Applicants respectfully request that these documents be listed as references cited on the issued patent.

Copies of United States patents and United States published patent applications do not have to be provided to the Patent Office (37 C.F.R. 1.98(a)(2)(ii)). Copies of unpublished U.S. applications do not have to be provided, as long as the application is available on PAIR, as this requirement of 37 C.F.R. § 1.98(a)(2)(iii) has been waived by the United States Patent and Trademark Office pursuant to the Official Gazette Notice on October 19, 2004 (1287 OG 163). Applicants will provide copies of such patents or applications upon request.


Applicants are filing this Information Disclosure Statement ("IDS") before the mailing of a first Office action on the merits. It is believed that no fee is due to file this IDS. If the Commissioner determines that a fee is due, Deposit Account authority is provided on the accompanying transmittal letter.

The filing of this IDS shall not be construed to be an admission that the information cited in the statement is, or is considered to be, prior art or otherwise material to patentability as defined in 37 C.F.R. §1.56.

Respectfully submitted,


KLARQUIST SPARKMAN, LLP

By



Tanya M. Harding, Ph.D.  
Registration No. 42,630

One World Trade Center, Suite 1600  
121 S.W. Salmon Street  
Portland, Oregon 97204  
Telephone: (503) 226-7391  
Facsimile: (503) 228-9446



# **INFORMATION DISCLOSURE STATEMENT BY APPLICANT**

Attorney Docket Number	4239-66645-01
Application Number	10/700,313
Filing Date	October 31, 2003
First Named Inventor	Combadiere
Art Unit	1616
Examiner Name	

## **U.S. PATENT DOCUMENTS**

Copies of U.S. Patent documents do not need to be provided, unless requested by the Patent and Trademark Office. For patents, provide the patent number and the issue date. For published U.S. applications, provide the publication number and the publication date. For unpublished pending patent applications, provide the application number and the filing date.

Examiner's Initials*	Cite No. (optional)	Number	Publication Date	Name of Applicant or Patentee
		5,939,320	Aug. 17, 1999	Littman <i>et al.</i>

## **FOREIGN PATENT DOCUMENTS**

Examiner's Initials*	Cite No. (optional)	Country	Number	Publication Date	Name of Applicant or Patentee


## **OTHER DOCUMENTS**

Examiner's Initials*	Cite No. (optional)	
		Deng <i>et al.</i> , "Identification of a major co-receptor for primary isolates of HIV-1," <i>Nature</i> 381:661-666 (June 20, 1998)

EXAMINER  
SIGNATURE:

DATE  
CONSIDERED:

\* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.



PATENT  
Attorney Reference Number 4239-66645-01

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

**In re application of:** Combadiere et al.

**Application No.** 10/700,313

**Filed:** October 31, 2003

**Confirmation No.** 5461

**For:** CC CHEMOKINE RECEPTOR 5 DNA,  
NEW ANIMAL MODELS AND  
THERAPEUTIC AGENTS FOR HIV  
INFECTION

**Examiner:**

**Art Unit:** 1616

**Attorney Reference No.** 4239-66645-01

COMMISSIONER FOR PATENTS  
P.O. BOX 1450  
ALEXANDRIA, VA 22313-1450

**CERTIFICATE OF MAILING**

I hereby certify that this paper and the documents referred to as being attached or enclosed herewith are being deposited with the United States Postal Service as First Class Mail in an envelope addressed to: COMMISSIONER FOR PATENTS, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450 on the date shown below.

Attorney  
for Applicant(s)

Tanya M. Harding, Ph.D.

Date Mailed April 8, 2005

**TRANSMITTAL LETTER**

Enclosed for filing in the application referenced above are the following:

- ☒ Information Disclosure Statement  
☒ Form 1449 and one reference cited thereon

The Director is hereby authorized to charge any additional fees that may be required, or credit over-payment, to Deposit Account No. 02-4550. A copy of this sheet is enclosed. Please return the enclosed postcard to confirm that the items listed above have been received.

Respectfully submitted,

KLARQUIST SPARKMAN, LLP

By

Tanya M. Harding, Ph.D.  
Registration No. 42,630

One World Trade Center, Suite 1600  
121 S.W. Salmon Street  
Portland, Oregon 97204  
Telephone: (503) 226-7391  
Facsimile: (503) 228-9446

cc: Docketing